絞り込み

16421

広告

Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs.

著者 Lee CK , Kim S , Lee JS , Lee JE , Kim SM , Yang IS , Kim HR , Lee JH , Kim S , Cho BC
Lung Cancer.2017 Nov ; 113():106-114.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (35view , 1users)

Full Text Sources

Miscellaneous

Despite initial responses to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in EGFR mutant non-small cell lung cancer, patients invariably develop acquired resistance. In this study, we performed next-generation sequencing in pre- and post-EGFR-TKI tumor samples to identify novel resistance mechanisms to EGFR-TKIs.
PMID: 29110836 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード